marketcaparena
Search

    IRWD

    IRONWOOD PHARMACEUTICALS INC

    Company overview

    Market capitalization
    $680.79M
    Employees
    100
    Latest publication
    2026-09-29
    About IRONWOOD PHARMACEUTICALS INC

    Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue113,041,000USD106,506,000USD47,709,000USD122,060,000USD85,239,000USD90,545,000USD91,592,000USD94,396,000USD
    Cost Of Revenue0USD443,000USD460,000USD475,000USD467,000USD78,478,000USD29,827,000USD506,000USD
    Gross Profit113,041,000USD106,063,000USD47,709,000USD121,585,000USD84,772,000USD90,545,000USD61,765,000USD94,396,000USD
    Research Development22,421,000USD21,497,000USD21,863,000USD21,993,000USD22,906,000USD25,391,000USD29,827,000USD30,388,000USD
    Selling General Administrative11,313,000USD12,033,000USD19,293,000USD21,908,000USD16,795,000USD33,590,000USD36,113,000USD36,964,000USD
    Total Operating Expenses33,734,000USD33,530,000USD41,156,000USD43,901,000USD39,701,000USD59,054,000USD36,129,000USD69,419,000USD
    Operating Income79,307,000USD72,533,000USD6,553,000USD77,684,000USD45,071,000USD31,491,000USD25,636,000USD24,977,000USD
    Total Other Income Expense Net-5,576,000USD-7,361,000USD-6,098,000USD-9,664,000USD-7,249,000USD-7,496,000USD-8,267,000USD-6,101,000USD
    Interest Expense7,203,000USD9,141,000USD7,886,000USD8,434,000USD8,356,000USD8,914,000USD9,419,000USD7,470,000USD
    Income Before Tax73,731,000USD65,172,000USD455,000USD68,020,000USD37,822,000USD23,995,000USD17,369,000USD18,876,000USD
    Income Tax Expense22,440,000USD24,399,000USD2,731,000USD27,940,000USD14,223,000USD21,739,000USD13,723,000USD19,736,000USD
    Net Income51,291,000USD40,773,000USD-2,276,000USD40,080,000USD23,599,000USD2,256,000USD3,646,000USD-860,000USD
    Interest Income—1,698,000USD1,459,000USD930,000USD818,000USD778,000USD1,152,000USD1,369,000USD
    Net Interest Income—-7,443,000USD-6,427,000USD-7,504,000USD-7,538,000USD-8,136,000USD-8,267,000USD-6,101,000USD
    Tax Provision—24,399,000USD2,731,000USD27,940,000USD14,223,000USD21,739,000USD13,723,000USD19,736,000USD
    Net Income From Continuing Ops—40,773,000USD-2,276,000USD40,080,000USD23,599,000USD2,256,000USD3,646,000USD-860,000USD
    Ebit—74,313,000USD8,341,000USD76,454,000USD46,178,000USD32,909,000USD26,788,000USD26,346,000USD
    Ebitda—74,756,000USD8,801,000USD76,929,000USD46,645,000USD33,394,000USD27,295,000USD26,852,000USD
    Depreciation And Amortization—443,000USD460,000USD475,000USD467,000USD485,000USD507,000USD506,000USD
    Reconciled Depreciation—443,000USD460,000USD475,000USD467,000USD485,000USD507,000USD506,000USD
    Minority Interest—————0USD0USD0USD
    Unclassified Operating Expenses——————-29,811,000USD2,067,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20112011-12-31 · USDFY 20082008-12-31 · USDFY 20072007-12-31 · USD
    Total Revenue296,151,000USD351,410,000USD410,596,000USD413,753,000USD389,523,000USD65,871,000USD22,216,000USD10,464,000USD
    Cost Of Revenue1,881,000USD7,552,000USD1,418,000USD70,405,000USD3,136,000USD122,014,000USD75,288,000USD66,348,000USD
    Gross Profit296,151,000USD343,858,000USD409,178,000USD343,348,000USD386,387,000USD65,871,000USD22,216,000USD10,464,000USD
    Research Development95,136,000USD111,421,000USD44,265,000USD70,405,000USD88,062,000USD86,093,000USD59,809,000USD57,246,000USD
    Selling General Administrative82,256,000USD144,272,000USD115,994,000USD111,133,000USD140,003,000USD45,920,000USD——
    Total Operating Expenses177,392,000USD250,734,000USD158,841,000USD111,089,000USD243,447,000USD132,013,000USD78,137,000USD68,079,000USD
    Operating Income118,759,000USD93,124,000USD250,337,000USD232,259,000USD142,940,000USD-66,142,000USD-55,921,000USD-57,615,000USD
    Interest Income4,076,000USD4,468,000USD9,501,000USD726,000USD1,504,000USD———
    Interest Expense32,746,000USD33,034,000USD7,598,000USD31,150,000USD29,478,000USD63,000USD334,000USD263,000USD
    Net Interest Income-28,670,000USD-28,566,000USD1,903,000USD-30,424,000USD-27,974,000USD———
    Income Before Tax70,025,000USD65,197,999USD252,422,000USD200,657,000USD108,861,000USD-64,849,000USD-55,031,000USD-53,160,000USD
    Income Tax Expense46,008,000USD64,318,000USD77,357,000USD-327,791,000USD2,685,000USD3,000USD-823,000USD-145,000USD
    Tax Provision46,008,000USD64,318,000USD77,357,000USD-327,791,000USD2,685,000USD———
    Net Income24,017,000USD880,000USD175,065,000USD528,448,000USD106,176,000USD-64,852,000USD-53,874,000USD-52,752,000USD
    Net Income From Continuing Ops24,017,000USD880,000USD175,065,000USD528,448,000USD106,176,000USD-64,852,000USD——
    Ebit102,771,000USD95,717,000USD260,020,000USD232,215,000USD138,339,000USD-64,786,000USD-54,697,000USD-52,897,000USD
    Ebitda104,652,000USD97,728,000USD261,438,000USD233,738,000USD141,903,000USD-54,787,000USD-51,848,000USD-51,166,000USD
    Depreciation And Amortization1,881,000USD2,011,000USD1,418,000USD1,523,000USD3,564,000USD9,999,000USD2,849,000USD1,731,000USD
    Reconciled Depreciation1,881,000USD2,011,000USD1,418,000USD1,523,000USD3,564,000USD———
    Total Other Income Expense Net-48,734,000USD-27,926,001USD2,085,000USD-31,602,000USD-34,079,000USD1,293,000USD890,000USD4,455,000USD
    Unclassified Operating Expenses—-4,959,000USD—-70,449,000USD15,382,000USD—18,328,000USD10,833,000USD
    Minority Interest—0USD0USD0USD————
    Non Operating Income Net Other——9,683,000USD-452,000USD-4,601,000USD1,356,000USD——
    Net Income Applicable To Common Shares——175,065,000USD528,448,000USD106,176,000USD-64,852,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets285,128,000USD434,566,000USD396,901,000USD396,062,000USD342,946,000USD327,213,000USD350,908,000USD389,519,000USD
    Cash And Equivalents79,127,000USD———————
    Total Current Assets199,201,000USD332,292,000USD274,178,000USD273,843,000USD191,753,000USD160,579,000USD182,368,000USD178,604,000USD
    Other Current Assets7,342,000USD5,979,000USD11,977,000USD13,066,000USD12,729,000USD12,330,000USD11,923,000USD14,191,000USD
    Other Non Current Assets3,874,000USD———————
    Total Liabilities446,971,000USD———————
    Total Current Liabilities32,854,000USD236,307,000USD242,218,000USD242,503,000USD232,525,000USD48,097,000USD38,846,000USD49,383,000USD
    Other Non Current Liabilities20,536,000USD———————
    Total Stockholder Equity-161,843,000USD-217,144,000USD-261,834,999USD-264,157,000USD-308,162,000USD-334,053,000USD-301,335,000USD-311,334,000USD
    Total Equity Including Noncontrolling Interest-161,843,000USD———————
    Net Receivables112,732,000USD105,842,000USD46,745,000USD120,370,000USD86,172,000USD39,768,000USD81,886,000USD76,202,000USD
    Property Plant Equipment Net11,356,000USD12,062,000USD12,748,000USD13,441,000USD14,130,000USD14,875,000USD15,523,000USD16,225,000USD
    Accounts Payable911,000USD3,237,000USD2,898,000USD1,613,000USD1,389,000USD5,827,000USD2,127,000USD3,236,000USD
    Short Term Debt3,285,000USD203,123,000USD202,932,000USD202,742,000USD202,552,000USD3,204,000USD3,189,000USD3,173,000USD
    Common Stock165,000USD165,000USD163,000USD163,000USD162,000USD162,000USD160,000USD160,000USD
    Retained Earnings-1,581,654,000USD-1,632,945,000USD-1,673,718,000USD-1,671,442,000USD-1,711,522,000USD-1,735,121,000USD-1,697,735,000USD-1,699,991,000USD
    Accumulated Other Comprehensive Income-324,000USD-795,000USD-1,060,000USD-1,714,000USD-2,026,000USD294,000USD923,000USD-2,052,000USD
    Intangible Assets—1,838,000USD2,040,000USD2,247,000USD2,453,000USD2,658,000USD2,860,000USD3,067,000USD
    Total Liab—651,710,000USD658,736,000USD660,219,000USD651,108,000USD661,266,000USD652,243,000USD700,853,000USD
    Other Current Liab—28,475,000USD35,281,000USD37,100,000USD26,842,000USD37,270,000USD30,977,000USD42,974,000USD
    Capital Stock—165,000USD163,000USD163,000USD162,000USD162,000USD160,000USD160,000USD
    Cash—220,471,000USD215,456,000USD140,407,000USD92,852,000USD108,481,000USD88,559,000USD88,211,000USD
    Cash And Short Term Investments—220,471,000USD215,456,000USD140,407,000USD92,852,000USD108,481,000USD88,559,000USD88,211,000USD
    Current Deferred Revenue—1,472,000USD1,107,000USD1,048,000USD978,000USD1,796,000USD2,032,000USD—
    Net Debt—376,885,000USD382,346,000USD457,833,000USD505,817,000USD490,600,000USD510,922,000USD526,661,000USD
    Short Long Term Debt—199,855,000USD199,680,000USD199,506,000USD199,332,000USD———
    Short Long Term Debt Total—597,356,000USD597,802,000USD598,240,000USD598,669,000USD599,081,000USD599,481,000USD614,872,000USD
    Long Term Debt—385,000,000USD385,000,000USD385,000,000USD385,000,000USD584,160,000USD583,988,000USD598,817,000USD
    Property Plant Equipment Gross—12,062,000USD20,753,000USD13,441,000USD14,130,000USD14,875,000USD23,888,000USD16,225,000USD
    Common Stock Shares Outstanding—166,690,000shares177,764,000shares177,764,000shares161,723,000shares160,974,000shares160,419,000shares160,232,000shares
    Non Current Assets Total—102,274,000USD122,723,000USD122,219,000USD151,193,000USD166,634,000USD168,540,000USD210,915,000USD
    Non Current Liabilities Total—415,403,000USD416,518,000USD417,716,000USD418,583,000USD613,169,000USD613,397,000USD651,470,000USD
    Non Current Liabilities Other—21,170,000USD21,648,000USD22,218,000USD22,466,000USD17,292,000USD17,105,000USD39,771,000USD
    Non Currrent Assets Other—4,137,000USD4,502,000USD4,844,000USD5,151,000USD5,538,000USD5,923,000USD6,285,000USD
    Net Working Capital—95,985,000USD31,960,000USD31,340,000USD-40,772,000USD112,482,000USD143,522,000USD129,221,000USD
    Unclassified Non Current Assets—84,237,000USD103,433,000USD101,687,000USD129,459,000USD143,563,000USD144,234,000USD185,338,000USD
    Unclassified Current Liabilities—-199,855,000USD-199,680,000USD-199,506,000USD-198,568,000USD———
    Unclassified Non Current Liabilities—9,233,000USD9,870,000USD10,498,000USD11,117,000USD11,717,000USD12,304,000USD12,882,000USD
    Unclassified Equity—1,416,266,000USD1,412,617,001USD1,408,673,000USD1,405,062,000USD1,400,450,000USD1,395,157,000USD1,390,389,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets396,901,000USD350,908,000USD471,073,000USD1,100,519,000USD1,126,927,000USD559,238,000USD402,748,000USD332,050,000USD
    Intangible Assets2,040,000USD2,860,000USD3,682,000USD—————
    Other Current Assets11,977,000USD11,923,000USD12,012,000USD7,715,000USD11,054,000USD9,189,000USD11,935,000USD12,313,000USD
    Total Liab658,736,000USD652,243,000USD817,368,000USD448,141,000USD521,016,000USD496,598,000USD495,999,000USD528,421,000USD
    Total Stockholder Equity-261,834,999USD-301,335,000USD-346,295,000USD652,378,000USD605,911,000USD62,640,000USD-93,251,000USD-196,371,000USD
    Other Current Liab35,281,000USD30,977,000USD61,721,000USD21,321,000USD40,778,000USD28,384,000USD33,421,000USD57,006,000USD
    Common Stock163,000USD160,000USD156,000USD154,000USD162,000USD161,000USD158,000USD154,000USD
    Capital Stock163,000USD160,000USD156,000USD154,000USD162,000USD161,000USD158,000USD154,000USD
    Retained Earnings-1,673,718,000USD-1,697,735,000USD-1,698,615,000USD-696,376,000USD-937,608,000USD-1,466,056,000USD-1,572,232,000USD-1,591,128,000USD
    Cash215,456,000USD88,559,000USD92,154,000USD656,203,000USD620,129,000USD364,299,000USD177,023,000USD173,172,000USD
    Cash And Short Term Investments215,456,000USD88,559,000USD92,154,000USD656,203,000USD620,129,000USD364,299,000USD177,023,000USD173,172,000USD
    Total Current Assets274,178,000USD182,368,000USD233,288,000USD780,626,000USD745,225,000USD495,839,000USD306,852,000USD266,435,000USD
    Total Current Liabilities242,218,000USD38,846,000USD276,101,000USD25,525,000USD161,698,000USD32,173,000USD40,929,000USD119,524,000USD
    Current Deferred Revenue1,107,000USD2,032,000USD2,620,000USD—39,462,000USD28,384,000USD875,000USD252,000USD
    Net Debt382,346,000USD510,922,000USD623,384,000USD-240,288,000USD-144,327,000USD89,403,000USD254,199,000USD240,751,000USD
    Short Term Debt202,932,000USD3,189,000USD202,686,000USD3,065,000USD119,985,000USD3,128,000USD1,146,000USD47,627,000USD
    Short Long Term Debt199,680,000USD—199,560,000USD—116,858,000USD——47,554,000USD
    Short Long Term Debt Total597,802,000USD599,481,000USD715,538,000USD415,915,000USD475,802,000USD453,702,000USD431,222,000USD413,923,000USD
    Long Term Debt385,000,000USD583,988,000USD498,309,000USD396,251,000USD337,333,000USD430,256,000USD407,994,000USD366,138,000USD
    Net Receivables46,745,000USD81,886,000USD129,122,000USD115,458,000USD114,042,000USD122,351,000USD117,246,000USD80,950,000USD
    Accounts Payable2,898,000USD2,127,000USD7,830,000USD483,000USD935,000USD661,000USD5,487,000USD14,891,000USD
    Property Plant Equipment Net12,748,000USD15,523,000USD18,171,000USD20,311,000USD22,925,000USD25,505,000USD30,172,000USD17,270,000USD
    Property Plant Equipment Gross20,753,000USD23,888,000USD27,060,000USD20,311,000USD22,925,000USD25,505,000USD30,172,000USD17,270,000USD
    Accumulated Other Comprehensive Income-1,060,000USD923,000USD-3,031,000USD0USD0USD-11,805,000USD-10,082,000USD0USD
    Common Stock Shares Outstanding177,764,000shares160,084,000shares155,435,000shares186,312,000shares164,418,000shares160,655,000shares156,023,000shares152,634,000shares
    Non Current Assets Total122,723,000USD168,540,000USD237,785,000USD319,893,000USD381,702,000USD63,399,000USD95,896,000USD65,615,000USD
    Non Current Liabilities Total416,518,000USD613,397,000USD541,267,000USD422,616,000USD359,318,000USD464,425,000USD455,070,000USD408,897,000USD
    Non Current Liabilities Other21,648,000USD17,105,000USD28,415,000USD9,766,000USD3,501,000USD1,763,000USD734,000USD2,530,000USD
    Non Currrent Assets Other4,502,000USD5,923,000USD3,608,000USD847,000USD25,483,000USD943,000USD64,939,000USD47,560,000USD
    Net Working Capital31,960,000USD143,522,000USD-42,813,000USD755,101,000USD583,527,000USD463,666,000USD265,923,000USD146,911,000USD
    Unclassified Non Current Assets103,433,000USD144,234,000USD212,323,999USD-15,436,000USD-49,481,000USD-54,770,000USD-128,902,000USD-98,198,000USD
    Unclassified Current Liabilities-199,680,000USD—-198,316,000USD—-156,320,000USD-28,384,000USD—-47,806,000USD
    Unclassified Non Current Liabilities9,870,000USD12,304,000USD14,543,000USD6,833,000USD14,983,000USD7,007,000USD—-42,443,000USD
    Unclassified Equity1,412,617,001USD1,395,157,000USD1,355,039,000USD1,348,446,000USD1,543,195,000USD1,540,179,000USD1,488,747,000USD1,394,449,000USD
    Other Assets——1USD299,582,000USD358,777,000USD54,470,000USD64,939,000USD57,178,000USD
    Inventory——1USD1,250,000USD1,250,000USD1USD648,000USD0USD
    Other Liab———9,766,000USD3,501,000USD13,311,000USD24,994,000USD42,601,000USD
    Long Term Investments———14,589,000USD23,998,000USD36,466,000USD63,963,000USD41,020,000USD
    Net Tangible Assets———668,977,000USD605,911,000USD82,958,000USD-71,954,000USD-197,156,000USD
    Deferred Long Term Liab—————12,088,000USD24,260,000USD40,071,000USD
    Good Will—————785,000USD785,000USD785,000USD
    Short Term Investments———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Net Income40,773,000USD40,080,000USD23,599,000USD-37,386,000USD3,189,000USD3,646,000USD-860,000USD-4,162,000USD
    Depreciation443,000USD475,000USD467,000USD479,000USD485,000USD507,000USD506,000USD513,000USD
    Stock Based Compensation3,653,000USD3,612,000USD4,524,000USD5,291,000USD4,566,000USD8,329,000USD8,570,000USD8,385,000USD
    Other Non Cash Items863,000USD851,000USD919,000USD825,000USD4,048,000USD355,000USD587,000USD622,000USD
    Change To Account Receivables-59,097,000USD-34,193,000USD-46,400,000USD42,118,000USD-5,684,000USD-18,095,000USD13,908,000USD57,107,000USD
    Change In Working Capital-59,807,000USD-25,207,000USD-58,682,000USD50,075,000USD-33,612,000USD-10,633,000USD11,407,000USD33,577,000USD
    Total Cash From Operating Activities5,121,000USD47,583,000USD-15,068,000USD19,954,000USD15,214,000USD9,885,000USD33,465,000USD44,985,000USD
    Capital Expenditures0USD-2,000USD-2,000USD-31,000USD-16,000USD-16,000USD-58,000USD-68,000USD
    Free Cash Flow5,121,000USD47,581,000USD-15,070,000USD19,923,000USD15,214,000USD9,869,000USD33,407,000USD44,917,000USD
    Total Cash From Financing Activities0USD0USD88,000USD6,000USD-14,887,000USD-27,156,000USD-49,372,000USD-15,555,000USD
    Change In Cash5,015,000USD47,555,000USD-15,629,000USD19,922,000USD348,000USD-17,313,000USD-16,016,000USD29,386,000USD
    Begin Period Cash Flow215,456,000USD92,852,000USD108,481,000USD88,559,000USD88,211,000USD105,524,000USD121,540,000USD92,154,000USD
    End Period Cash Flow220,471,000USD140,407,000USD92,852,000USD108,481,000USD88,559,000USD88,211,000USD105,524,000USD121,540,000USD
    Unclassified Operating Cash Flow19,196,000USD27,772,000USD14,105,000USD—36,538,000USD7,681,000USD13,255,000USD6,050,000USD
    Investments—-2,000USD-2,000USD-31,000USD0USD-16,000USD-58,000USD-68,000USD
    Total Cashflows From Investing Activities—-2,000USD-2,000USD-31,000USD-16,000USD-16,000USD-58,000USD-68,000USD
    Net Borrowings—0USD0USD0USD-15,000,000USD-25,000,000USD——
    Other Cashflows From Investing Activities—-2,000USD———-16,000USD-58,000USD—
    Other Cashflows From Financing Activities——88,000USD6,000USD-2,246,000USD-2,156,000USD-121,000USD-616,000USD
    Unclassified Financing Cash Flow————2,359,000USD—-49,251,000USD-14,323,000USD
    Sale Purchase Of Stock———————-616,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income24,017,000USD880,000USD-1,002,239,000USD175,065,000USD528,448,000USD106,176,000USD21,505,000USD-282,368,000USD
    Depreciation1,881,000USD2,011,000USD1,575,000USD1,418,000USD1,500,000USD3,564,000USD5,580,000USD14,223,000USD
    Stock Based Compensation17,250,000USD29,850,000USD32,005,000USD27,048,000USD22,281,000USD31,175,000USD31,278,000USD43,977,000USD
    Other Non Cash Items3,445,000USD1,979,000USD1,068,170,000USD1,673,000USD25,229,000USD22,263,000USD52,355,000USD-13,444,000USD
    Change To Account Receivables35,148,000USD47,236,000USD924,000USD7,993,000USD7,712,000USD4,091,000USD-68,893,000USD1,207,000USD
    Change In Working Capital39,650,000USD739,000USD11,279,000USD2,820,000USD17,731,000USD-941,000USD-99,993,000USD7,616,000USD
    Total Cash From Operating Activities127,044,000USD103,549,000USD183,427,000USD273,763,000USD261,895,000USD168,836,000USD10,725,000USD-70,882,000USD
    Capital Expenditures-34,000USD-142,000USD-273,000USD-136,000USD-265,000USD-1,842,000USD-7,189,000USD-8,621,000USD
    Free Cash Flow127,010,000USD103,407,000USD183,154,000USD273,627,000USD261,630,000USD166,994,000USD3,536,000USD-79,503,000USD
    Total Cashflows From Investing Activities-34,000USD-142,000USD-1,026,318,000USD-136,000USD-265,000USD-1,842,000USD-11,144,000USD88,866,000USD
    Net Borrowings0USD-115,000,000USD300,000,000USD-120,699,000USD-120,699,000USD-120,699,000USD16,253,000USD-1,824,000USD
    Total Cash From Financing Activities216,000USD-106,970,000USD277,160,000USD-237,553,000USD-4,550,000USD18,546,000USD-1,185,000USD30,072,000USD
    Change In Cash126,897,000USD-3,595,000USD-565,784,000USD36,074,000USD257,080,000USD185,540,000USD-1,604,000USD48,056,000USD
    Begin Period Cash Flow88,559,000USD92,154,000USD657,938,000USD621,864,000USD364,784,000USD179,244,000USD180,848,000USD132,792,000USD
    End Period Cash Flow215,456,000USD88,559,000USD92,154,000USD657,938,000USD621,864,000USD364,784,000USD179,244,000USD180,848,000USD
    Other Cashflows From Financing Activities216,000USD-2,983,000USD-29,197,000USD111,159,000USD19,581,000USD18,546,000USD-20,612,000USD31,896,000USD
    Unclassified Operating Cash Flow40,801,000USD68,090,000USD72,637,000USD65,739,000USD-333,294,000USD6,599,000USD—159,114,000USD
    Investments—-142,000USD-1,022,103,000USD-136,000USD-265,000USD-1,842,000USD-11,144,000USD95,924,000USD
    Sale Purchase Of Stock—0USD0USD-126,394,000USD-24,131,000USD18,546,000USD13,595,000USD32,061,000USD
    Unclassified Financing Cash Flow—11,013,000USD6,357,000USD9,540,000USD120,699,000USD102,153,000USD-10,421,000USD-32,061,000USD
    Change To Inventory———0USD0USD648,000USD725,000USD-806,000USD
    Change To Liabilities———-7,930,000USD10,084,000USD-7,552,000USD-33,183,000USD8,963,000USD
    Dividends Paid———-111,159,000USD————
    Cash And Cash Equivalents Changes———36,074,000USD257,080,000USD185,540,000USD-1,604,000USD48,056,000USD
    Unclassified Investing Cash Flow—————1,842,000USD11,144,000USD—
    Other Cashflows From Investing Activities——————-3,955,000USD1,563,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2019Quarterly · 2019-03-31ProductActive Pharmaceutical Ingredient2,578,000USD0001558370-19-003848
    Q1 2019Quarterly · 2019-03-31ProductCollaborative Arrangements66,152,000USD0001558370-19-003848
    Q4 2018Quarterly · 2018-12-31ProductActive Pharmaceutical Ingredient45,861,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31ProductCollaborative Arrangements84,352,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31ProductProduct479,000USDLegacy provider
    FY 2018Yearly · 2018-12-31ProductActive Pharmaceutical Ingredient70,355,000USD0001558370-21-001136
    FY 2018Yearly · 2018-12-31ProductCollaborative Arrangement Co Promotion Agreement4,290,000USD0001558370-21-001136
    FY 2018Yearly · 2018-12-31ProductCollaborative Arrangement Other Agreements1,226,000USD0001558370-21-001136
    FY 2018Yearly · 2018-12-31ProductCollaborative Arrangements272,839,000USD0001558370-21-001136
    Q3 2018Quarterly · 2018-09-30ProductActive Pharmaceutical Ingredient10,257,000USD0001558370-19-009567
    Q3 2018Quarterly · 2018-09-30ProductCollaborative Arrangement Co Promotion Agreement800,000USD0001558370-19-009567
    Q3 2018Quarterly · 2018-09-30ProductCollaborative Arrangement Other Agreements465,000USD0001558370-19-009567
    Q3 2018Quarterly · 2018-09-30ProductCollaborative Arrangements54,194,000USD0001558370-19-009567
    Q2 2018Quarterly · 2018-06-30ProductActive Pharmaceutical Ingredient8,803,000USD0001558370-19-006578
    Q2 2018Quarterly · 2018-06-30ProductCollaborative Arrangement Co Promotion Agreement800,000USD0001558370-19-006578
    Q2 2018Quarterly · 2018-06-30ProductCollaborative Arrangement Other Agreements343,000USD0001558370-19-006578
    Q2 2018Quarterly · 2018-06-30ProductCollaborative Arrangements71,207,000USD0001558370-19-006578
    Q1 2018Quarterly · 2018-03-31ProductActive Pharmaceutical Ingredient5,434,000USD0001558370-19-003848
    Q1 2018Quarterly · 2018-03-31ProductCollaborative Arrangements63,086,000USD0001558370-19-003848
    Q1 2018Quarterly · 2018-03-31ProductProduct635,000USD0001558370-19-003848
    FY 2017Yearly · 2017-12-31ProductActive Pharmaceutical Ingredient29,682,000USD0001558370-20-000779
    FY 2017Yearly · 2017-12-31ProductCollaborative Arrangement Co Promotion Agreement4,079,000USD0001558370-20-000779
    FY 2017Yearly · 2017-12-31ProductCollaborative Arrangement Other Agreements419,000USD0001558370-20-000779
    FY 2017Yearly · 2017-12-31ProductCollaborative Arrangements265,533,000USD0001558370-20-000779
    Q3 2017Quarterly · 2017-09-30ProductActive Pharmaceutical Ingredient9,491,000USD0001558370-18-008641
    Q3 2017Quarterly · 2017-09-30ProductCollaborative Arrangements76,652,000USD0001558370-18-008641
    Q3 2017Quarterly · 2017-09-30ProductProduct682,000USD0001558370-18-008641
    Q2 2017Quarterly · 2017-06-30ProductActive Pharmaceutical Ingredient5,972,000USD0001558370-18-006445
    Q2 2017Quarterly · 2017-06-30ProductCollaborative Arrangements58,640,000USD0001558370-18-006445
    Q2 2017Quarterly · 2017-06-30ProductProduct465,000USD0001558370-18-006445
    Q1 2017Quarterly · 2017-03-31ProductActive Pharmaceutical Ingredient12,000USD0001558370-18-004028
    Q1 2017Quarterly · 2017-03-31ProductCollaborative Arrangements51,865,000USD0001558370-18-004028
    Q1 2017Quarterly · 2017-03-31ProductOther289,000USD0001558370-18-004028
    FY 2016Yearly · 2016-12-31ProductActive Pharmaceutical Ingredient9,925,000USD0001558370-19-001005
    FY 2016Yearly · 2016-12-31ProductCollaborative Arrangements263,923,000USD0001558370-19-001005
    FY 2016Yearly · 2016-12-31ProductProduct109,000USD0001558370-19-001005

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.